0000000000873733

AUTHOR

Jeffrey W. Sherman

showing 1 related works from this author

Teprotumumab for the treatment of active thyroid eye disease

2020

Abstract Background Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food and Drug Administration–approved medical therapy is available...

Drugmedicine.medical_specialtyBlindingmedia_common.quotation_subjectEye diseaseMedizin030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawOphthalmologymedicine030212 general & internal medicinemedia_commonTeprotumumabbusiness.industryThyroidGeneral Medicinemedicine.diseaseDermatologyeye diseasesClinical trialmedicine.anatomical_structuresense organsbusinessMedical therapymedicine.drug
researchProduct